INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Show more

225 NE Mizner Blvd., Boca Raton, FL, 33432, United States

https://www.inmunebio.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

33.5M

52 Wk Range

$1.21 - $11.64

Previous Close

$1.26

Open

$1.28

Volume

443,798

Day Range

$1.28 - $1.38

Enterprise Value

23.97M

Cash

27.73M

Avg Qtr Burn

-5.439M

Insider Ownership

18.80%

Institutional Own.

18.19%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CORDStrom Details Recessive dystrophic epidermolysis bullosa	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPro1595 (XPro™) Details Early Alzheimer's disease	Phase 2/3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INB03 + trastuzumab-deruxtecan Details Cancer, Pancreatic cancer, Gastric cancer, HER2-expressing cancers, Breast cancer, Triple-negative breast cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPro1595 (XPro™) (pegipanermin fr) Details Major depressive disorder, Mental health, Treatment Resistant Depression	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INKmune™ Details Cancer, Prostate cancer, Castration-resistant prostate cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.